Novartis's Afinitor receives first approval in US for kidney cancer
This article was originally published in Scrip
Executive Summary
Novartis's Afinitor (everolimus) has received its first worldwide approval for the treatment of advanced renal cell carcinoma (kidney cancer) in the US, for patients who have progressed on treatment with other targeted anticancer drugs approved for the disease.